{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:19:56Z","timestamp":1788268796753,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with myocardial infarction (MI), quantifying expression of platelet Fc\u0263RIIa (pFCG) stratifies risk of subsequent MI, stroke, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009749) were enrolled in a prospective non\u2010interventional trial during hospitalization with type 1 MI (ST elevation and non\u2010ST elevation). Inclusion criteria included \u2265\u20092 of the following clinical risk factors: age \u2265\u200965, multi\u2010vessel coronary artery disease, prior MI, chronic kidney disease, or diabetes mellitus. High and low pFCG (quantified by flow cytometry at a core laboratory) were defined by a prespecified threshold. The primary endpoint was the composite of MI, stroke, and death.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Distribution of clinical risk factors was 346 patients (45%) with 2 factors, 272 patients (36%) with 3 factors, and 131 patients (17%) with 4 or 5 factors. A greater number of risk factors was associated with a greater risk of the composite of MI, stroke, and death after 1 year. The event rate with 2 risk factors was 10.2%, with 3 factors it was 14.4%, and with 4\/5 factors it was 35.6%. Across all cohorts of clinical risk, the pFCG test identified a higher\u2010risk and a lower\u2010risk cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both clinical risk and the pFCG test assess prognosis. Results of the pFCG test refine the prognosis defined by clinical risk. The prognostic implications suggest that the pFCG test may be a useful tool to balance ischemic risk with that of bleeding to define treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05175261\">https:\/\/clinicaltrials.gov\/study\/NCT05175261<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ccd.70691","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:16:09Z","timestamp":1781669769000},"page":"662-668","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet Fc\u0263RIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction"],"prefix":"10.1002","volume":"108","author":[{"given":"David J.","family":"Schneider","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardiovascular Research Institute The University of Vermont Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"McMahon","sequence":"additional","affiliation":[{"name":"Department of Medicine Hartford Hospital Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology University of Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Fanaroff","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homam","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Adventist Healthcare White Oak Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick K.","family":"Hohl","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine Maine Medical Center Portland Maine USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Wanamaker","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine University of Michigan Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Effron","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute University of Queensland Ochsner Clinical School New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6431","authenticated-orcid":false,"given":"Peter M.","family":"DiBattiste","sequence":"additional","affiliation":[{"name":"Prolocor Inc Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"behalf of the investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3775"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009177"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00598-1"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00901-2"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.7.835"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.12.007"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314590"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.046"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.051"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2024.2395706"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5244"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa670"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.124.014939"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002822"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-001004"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.08.053"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01311-9"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa193"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccd.70691","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:44:24Z","timestamp":1788266664000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.70691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ccd.70691"],"URL":"https:\/\/doi.org\/10.1002\/ccd.70691","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2026-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}